Abstract
Objective:
To investigate if adjunctive valacyclovir, an antiviral medication, reduces symptoms of persistent schizophrenia in individuals who are seropositive for cytomegalovirus (CMV).
Method:
N=47 CMV seropositive schizophrenia outpatients were randomly assigned to receive valacyclovir 1 g twice daily (n=24) or placebo (n=23) for 16 weeks after a 2-week placebo run-in. Symptoms were assessed biweekly.
Results:
There was no significant difference in the change of positive, negative, general, or total PANSS symptoms between the valacyclovir vs. the placebo group.
Conclusions:
The study did not demonstrate benefit of adjunctive valacyclovir for schizophrenia individuals with persistent symptoms who are CMV seropositive.
Publication types
-
Randomized Controlled Trial
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Acyclovir / administration & dosage
-
Acyclovir / adverse effects
-
Acyclovir / analogs & derivatives*
-
Adult
-
Antipsychotic Agents / administration & dosage*
-
Antipsychotic Agents / adverse effects
-
Antiviral Agents / administration & dosage*
-
Antiviral Agents / adverse effects
-
Baltimore
-
Comorbidity
-
Cytomegalovirus Infections / drug therapy*
-
Cytomegalovirus Infections / epidemiology
-
Double-Blind Method
-
Drug Therapy, Combination
-
Female
-
Humans
-
Male
-
Middle Aged
-
Psychiatric Status Rating Scales*
-
Psychotic Disorders / drug therapy*
-
Psychotic Disorders / epidemiology
-
Schizophrenia / drug therapy*
-
Schizophrenia / epidemiology
-
Schizophrenic Psychology*
-
Valacyclovir
-
Valine / administration & dosage
-
Valine / adverse effects
-
Valine / analogs & derivatives*
Substances
-
Antipsychotic Agents
-
Antiviral Agents
-
Valine
-
Valacyclovir
-
Acyclovir